Also, clinical trials of therapies targeting Aβ/tau production, metabolism, and clearance have universally shown little efficacy making it likely that other proximal mechanisms of AD pathogenesis exist [33, 34]. The gene discussed is MAPT; the disease is Alzheimer disease.